|
|
Anthony |
|
Maida |
|
Chief Clinical Officer – Translational Medicine |
Oncotelic Therapeutics, Inc. |
https://proventainternational.com/wp-content/uploads/2022/02/Anthony-Maida-1.jpg |
Dr. Maida is currently Chief Clinical Officer – Translational Medicine for Oncotelic, Inc. focused on the immunotherapy of cancer and infectious disease. Formerly he was Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. He is responsible for the oversight of the clinical and scientific operations of Oncotelic Therapeutics, Inc. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions. For 30 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer. Dr. Maida’s skill set includes the execution and oversight of finance, operations, research, and commercial clinical and scientific development, regulatory and manufacturing for the development of various therapeutic modalities. Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc. Additionally, Dr. Maida has been retained by Abraxis BioScience, Inc., Northwest BioTherapeutics, Inc. and Takeda Chemical Industries, Ltd. (Osaka, Japan). Dr. Maida sat on multiple public company boards and advisory committees. Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches. |
|
|
Christie |
|
Quarles |
|
Clinical Analytics Product Marketing Manager |
Revvity Signals |
https://proventainternational.com/wp-content/uploads/2025/11/images-4.jpg |
|
|
|
David |
|
Crean |
|
Managing Partner & Partner |
Cardiff Advisory LLC & 1004 Venture Partners |
https://proventainternational.com/wp-content/uploads/2025/10/David-H.-Crean.jpg |
David H. Crean is a distinguished executive with over 30 years of experience across the life sciences and healthcare sectors with roles in strategic biopharma, private equity, venture capital, and investment banking. His career journey is a unique blend of scientific knowledge, business savvy, and financial leadership, which has earned him a reputation as a mentor, investor and dealmaker. Dr. Crean currently serves as the Founder and Managing Partner of Cardiff Advisory LLC, an M&A advisory firm, and is a Venture Partner at 1004 Venture Partners, a healthcare investment fund. He holds a Ph.D. in Biophysics and an M.S. in Oncology from the State University of New York Buffalo, as well as an MBA in Finance from Pepperdine University. |
|
|
Elie |
|
Arslan |
|
Head, Quality, Principal Investigator and Program Management |
Cellics Therapeutics, Inc. |
https://proventainternational.com/wp-content/uploads/2025/10/Elie-Arslan.jpg |
Compliance driven, highly successful Quality leader, with over 21 years of extensive experience in Quality in Biopharmaceuticals, Biologics, and Medical Devices. I am comprehensively knowledgeable and experienced in GxP (GMP, GLP and GCP), with an MBA and a Master of Science in Biotechnology from Johns Hopkins University. Elie oversees various Quality and Regulatory responsibilities and thrive in a fast-paced dynamic environment. Elie has 12 years of CMO experience, including experience in releasing drug substances, drug products, aseptic filling operations for clinical trials to commercial automated large-scale production, experience small molecules, large molecules, oncology and gene therapy. Elie successfully hosted FDA, CA FDB and QP inspections for PAI and routine Quality System inspections since 2015. |
|
|
George |
|
Ng |
|
Chief Executive Officer |
Processa Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2023/05/George-Ng.jpg |
George Ng is a seasoned executive and entrepreneur in the life sciences industry, currently serving as Chief Executive Officer and Board Director at Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) and as a partner at PENG Life Science Ventures (PENG LSV). Previously, he was President, COO, and Board Director at Calidi Biotherapeutics, Inc. (NYSE: CLDI), where he led the company’s successful public listing.
Mr. Ng co-founded Scilex Pharmaceuticals, Inc. (NASDAQ: SCLX), guiding it through product development, clinical trials, FDA approval, $140 million in financing, and its commercial launch and sale. His leadership career also includes senior executive roles at Sorrento Therapeutics, BioDelivery Sciences, Spectrum Pharmaceuticals, and Alpharma (now part of Pfizer), contributing to multiple successful drug product launches.
Before entering industry, Mr. Ng was a partner at two Am Law 200 firms, where he founded and led a national life sciences practice. He has served on the boards of several biotech companies and is a frequent speaker on legal, regulatory, and business topics.
Mr. Ng holds a Juris Doctor from the University of Notre Dame School of Law and a B.A.S. in Biochemistry and Economics from the University of California, Davis.
|
|
|
Glenn |
|
Guthrie |
|
Senior Principal Clinical Solutions Strategy |
Revvity Signals |
https://proventainternational.com/wp-content/uploads/2025/11/3a8daac2-0bdd-47f0-b82f-1845cb5def59_thumb.jpg |
With 18 years of experience developing medical and health-based visualizations and analytics, Glenn is a thought leader in oncology analytics and clinical data review. He has led technical engagements across small, mid, and large pharma, delivering Spotfire-powered clinical solutions that enhance oversight, pharmacovigilance, and operational workflows. His background spans neural networks, enterprise informatics, and customer-centric solution architecture. |
|
|
Jacqui |
|
Blem |
|
Vice President, Clinical Operations |
Wugen |
https://proventainternational.com/wp-content/uploads/2025/07/Jacqui-Blem.jpg |
|
|
|
Janal |
|
Urich |
|
Vice President, Clinical Operations |
Atara Biotherapeutics |
https://proventainternational.com/wp-content/uploads/2024/02/Janal-Urich.jpg |
Over 25 years industry biopharma experience, with roles in nearly every facet and phase of Drug Development. The past 13 years have been in small, emerging biopharma companies, largely focused on building, refining, and optimizing infrastructure to streamline drug development.
A particularly enjoyable aspect of working through infrastructure challenges is leveraging problem solving and interpersonal skills that are required to successfully identify, navigate, and solve strategic, tactical, and cultural requirements. These requirements are key considerations to ensure changes are a successful fit for the respective culture, their stage(s) of drug development, and most importantly, foster an efficient and effective drug development practice.
|
|
|
John |
|
Mattison |
|
Former Operating Partner, Chief Medical Information Officer |
Arsenal Capital Partners |
https://proventainternational.com/wp-content/uploads/2025/10/John-Mattison.jpg |
|
|
|
Joseph |
|
Shan |
|
Vice President, Clinical Operations |
Adcentrx Therapeutics |
https://proventainternational.com/wp-content/uploads/2024/02/Joseph-Shan.jpg |
Joseph (Joe) Shan, M.P.H., VP, Clinical Operations at Adcentrx Therapeutics, has nearly 30 years of clinical experience in biopharma and medical device companies. Nearly 25 years were focused on clinical development of oncology therapeutics, including radiopharmaceuticals, small molecules, targeted therapy, immunotherapy and cellular therapy. Prior to Adcentrx, Joe held leadership roles in Clinical Development Operations at Mosaic ImmunoEngineering, MEI Pharma, Elevar Therapeutics, Kiadis Pharma (formerly CytoSen Therapeutics) and was VP, Clinical & Regulatory Affairs and a corporate officer of Peregrine Pharmaceuticals for nearly a decade. Mr. Shan received his M.P.H. from George Washington University and B.S. from UCLA |
|
|
Peter |
|
Stiegler |
|
Vice President, Clinical Operations Oncology |
HUYA Bioscience International |
https://proventainternational.com/wp-content/uploads/2022/05/avatar.jpg |
|
|
|
Sandy |
|
Wiley |
|
Former Senior Director Nonclinical & Translational Sciences (Department Head) |
MEI Pharma |
https://proventainternational.com/wp-content/uploads/2025/11/Sandy-Wiley.jpg |
|
|
|
Shaun |
|
MacEachern |
|
Executive Director, Clinical Supply Chain |
Kumquat Biosciences Inc. |
https://proventainternational.com/wp-content/uploads/2025/09/Shaun-MacEachern.jpg |
|
|
|
Tara |
|
Lehner |
|
Vice President, Clinical Operations |
INmune Bio Inc. |
https://proventainternational.com/wp-content/uploads/2023/03/Tara-Lehner.jpg |
Ms. Lehner is Vice President of Clinical Operations at INmune Bio. She has spent over 24 years in the pharmaceutical industry as an employee and consultant working across pharma, biotech, and CROs in Phases I–IV, with a focus on oncology and CNS. She has led long-term strategic partnerships between CROs and pharma and emphasizes the humanness of business relationships. Ms. Lehner holds an MS from the Temple University School of Pharmacy. Tara lives on a ranch in Southern California with her partner and two daughters, ages 7 and 8. |
Clinical Operations
Clinical Trial Supply Chain
Hard Rock Hotel San Diego
Payment Securely powered by stripe
